Patient characteristics
| . | Donor source . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | MRD (N = 3511) . | MUD 10/10 (N = 1959) . | MUD 9/10 (N = 549) . | UCB (N = 333) . | Haplo (N = 193) . | |||||
| Sex | P = .019 | |||||||||
| Male | 1809 | 52% | 1034 | 53% | 275 | 50% | 146 | 44% | 110 | 57% |
| Female | 1701 | 48% | 925 | 47% | 273 | 50% | 187 | 56% | 83 | 43% |
| Age, y | P < .001 | |||||||||
| Median | 50 | 54 | 52 | 48 | 51 | |||||
| Range | 18-74 | 18-80 | 18-74 | 18-72 | 18-75 | |||||
| WBC at diagnosis | P = .009 | |||||||||
| >100 | 1716 | 49% | 897 | 46% | 264 | 48% | 177 | 53% | 69 | 36% |
| ≤100 | 435 | 12% | 176 | 9% | 47 | 9% | 36 | 11% | 8 | 4% |
| Missing | 1360 | 39% | 886 | 45% | 238 | 43% | 120 | 36% | 116 | 60% |
| Secondary AML | P < .001 | |||||||||
| No | 2207 | 63% | 1068 | 55% | 318 | 58% | 208 | 62% | 116 | 60% |
| Yes | 1304 | 37% | 891 | 45% | 231 | 42% | 125 | 38% | 77 | 40% |
| Poor-risk cytogenetics (−7/−5/complex/11q23) | P = .016 | |||||||||
| No | 2028 | 58% | 1109 | 57% | 300 | 55% | 163 | 49% | 101 | 52% |
| Yes | 1483 | 42% | 850 | 43% | 249 | 45% | 170 | 51% | 92 | 48% |
| FLT3-ITD | P < .001 | |||||||||
| No | 366 | 10% | 271 | 14% | 83 | 15% | 53 | 16% | 50 | 26% |
| Yes | 605 | 17% | 353 | 18% | 101 | 18% | 72 | 22% | 42 | 22% |
| Missing | 2540 | 72% | 1335 | 68% | 365 | 66% | 208 | 62% | 101 | 52% |
| CR reached after | P < .001 | |||||||||
| Cycle 1 (early CR) | 2536 | 72% | 1529 | 78% | 404 | 74% | 253 | 76% | 144 | 75% |
| Cycle 2 (late CR) | 975 | 28% | 430 | 22% | 145 | 26% | 80 | 24% | 49 | 25% |
| Time from diagnosis to PRT, mo | P < .001 | |||||||||
| Median | 4.7 | 5.6 | 6.1 | 5.9 | 6.2 | |||||
| IQR | 3.7-6.1 | 4.3-7.2 | 4.7-8.1 | 4.8-7.8 | 4.5-8.7 | |||||
| Year of PRT | P < .001 | |||||||||
| Median | 2008 | 2011 | 2011 | 2010 | 2012 | |||||
| Range | 2000-2014 | 2000-2014 | 2000-2014 | 2000-2014 | 2000-2014 | |||||
| . | Donor source . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | MRD (N = 3511) . | MUD 10/10 (N = 1959) . | MUD 9/10 (N = 549) . | UCB (N = 333) . | Haplo (N = 193) . | |||||
| Sex | P = .019 | |||||||||
| Male | 1809 | 52% | 1034 | 53% | 275 | 50% | 146 | 44% | 110 | 57% |
| Female | 1701 | 48% | 925 | 47% | 273 | 50% | 187 | 56% | 83 | 43% |
| Age, y | P < .001 | |||||||||
| Median | 50 | 54 | 52 | 48 | 51 | |||||
| Range | 18-74 | 18-80 | 18-74 | 18-72 | 18-75 | |||||
| WBC at diagnosis | P = .009 | |||||||||
| >100 | 1716 | 49% | 897 | 46% | 264 | 48% | 177 | 53% | 69 | 36% |
| ≤100 | 435 | 12% | 176 | 9% | 47 | 9% | 36 | 11% | 8 | 4% |
| Missing | 1360 | 39% | 886 | 45% | 238 | 43% | 120 | 36% | 116 | 60% |
| Secondary AML | P < .001 | |||||||||
| No | 2207 | 63% | 1068 | 55% | 318 | 58% | 208 | 62% | 116 | 60% |
| Yes | 1304 | 37% | 891 | 45% | 231 | 42% | 125 | 38% | 77 | 40% |
| Poor-risk cytogenetics (−7/−5/complex/11q23) | P = .016 | |||||||||
| No | 2028 | 58% | 1109 | 57% | 300 | 55% | 163 | 49% | 101 | 52% |
| Yes | 1483 | 42% | 850 | 43% | 249 | 45% | 170 | 51% | 92 | 48% |
| FLT3-ITD | P < .001 | |||||||||
| No | 366 | 10% | 271 | 14% | 83 | 15% | 53 | 16% | 50 | 26% |
| Yes | 605 | 17% | 353 | 18% | 101 | 18% | 72 | 22% | 42 | 22% |
| Missing | 2540 | 72% | 1335 | 68% | 365 | 66% | 208 | 62% | 101 | 52% |
| CR reached after | P < .001 | |||||||||
| Cycle 1 (early CR) | 2536 | 72% | 1529 | 78% | 404 | 74% | 253 | 76% | 144 | 75% |
| Cycle 2 (late CR) | 975 | 28% | 430 | 22% | 145 | 26% | 80 | 24% | 49 | 25% |
| Time from diagnosis to PRT, mo | P < .001 | |||||||||
| Median | 4.7 | 5.6 | 6.1 | 5.9 | 6.2 | |||||
| IQR | 3.7-6.1 | 4.3-7.2 | 4.7-8.1 | 4.8-7.8 | 4.5-8.7 | |||||
| Year of PRT | P < .001 | |||||||||
| Median | 2008 | 2011 | 2011 | 2010 | 2012 | |||||
| Range | 2000-2014 | 2000-2014 | 2000-2014 | 2000-2014 | 2000-2014 | |||||
IQR, interquartile range; PRT, postremission treatment.